---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-23-006600"
form_type: "8-K"
ticker: "SANA"
cik: "0001770121"
company_name: "Sana Biotechnology, Inc."
filed_at: "2023-04-28T23:59:59+00:00"
generated_at: "2026-06-16T06:38:50.583813+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Sana Biotechnology announces departure of Sunil Agarwal as EVP, Head of Development and CMO

## Summary
- Separation effective April 28, 2023; Sunil Agarwal to provide transition services under a Transition Agreement.
- Severance of $560,523 (9 months base salary plus pro-rata bonus) plus COBRA coverage for up to 9 months.
- Acceleration of 89,377 unvested stock options; exercise period extended to December 31, 2023.
- Consulting Agreement at $256/hour, effective April 29, 2023, ending May 12 or extended to May 26, 2023.

## SEC filing metadata
- accession: 0001564590-23-006600
- form_type: 8-K
- ticker: SANA
- cik: 0001770121
- company_name: Sana Biotechnology, Inc.
- filed_at: 2023-04-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770121/000156459023006600/0001564590-23-006600-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770121/000156459023006600/sana-8k_20230428.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-23-006600
- JSON: https://secwatch.observer/filing/0001564590-23-006600.json
- Plain text: https://secwatch.observer/filing/0001564590-23-006600.txt

## Key facts
- Executive change
  Sunil Agarwal resigned as Executive Vice President, Head of Development, and Chief Medical Officer at Sana Biotechnology, Inc..
  - Action: resigned
  - Role: Executive Vice President, Head of Development, and Chief Medical Officer
  source text: Sana Biotechnology, Inc. (the “Company”) previously filed a Current Report on Form 8-K disclosing the resignation of Sunil Agarwal, M.D. as the Company’s Executive Vice President, Head of Development, and Chief Medical Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770121/000156459023006600/0001564590-23-006600-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.